ArticleMikrochimica acta2025
Integrated SERS and photothermal dual-mode ultrasensitive immunochromatographic detection for influenza A based on PDA@Au nanoprobes.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A multifunctional polydopamine-gold (PDA@Au) core-shell nanoprobe has been synthesized that simultaneously enables surface-enhanced Raman scattering (SERS), photothermal conversion, and visual signal output within a single structure. Based on these features, we developed a dual-modal LFA platform for H1N1 antigens detection through two complementary readout modes. The SERS and photothermal modes achieved detection limits of 1.34 pg/mL and 1.03 pg/mL, corresponding to 746-fold and 971-fold improvements compared to commercial Au-based LFAs. The platform also exhibited excellent specificity against other common respiratory viruses and high batch-to-batch reproducibility across detection modes. Clinical validation on 90 throat swab specimens showed strong agreement with RT-PCR results. The PDA@Au-LFA demonstrated sensitivities of 98.5% (SERS), 97.0% (photothermal), and 93.9% (visual), along with consistently high specificity (95.8%). These results highlight the PDA@Au-based LFA as a high-performance diagnostic platform, featuring sensitive, specific, and reproducible multimodal detection enabled by the integration of a novel signal transduction material.
Indexed as
Identifiers
41214371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.